Training on Good Regulatory Practices and their Implementation in the Medical Device Sector Mexico Session III

Pharmacopoeia of the United Mexican States Supplement for Medical Devices







November 17th, 2021



Regulatory context in Mexico

It is a matter of general health

The **sanitary control** of the process, use, maintenance, import, export and final disposal of medical equipment, prostheses, orthoses, functional aids, diagnostic agents, dental supplies, surgical materials, healing and hygienic products

Article 3, section XXIII of the General Health Law.



Regulatory context in Mexico

What is health control?

"(...) health control is understood as the set of actions of orientation, What education, sampling, verification and, where appropriate, application of security measures and sanctions, exercised by the Secretariat of Who Health with the participation of producers, marketers and consumers, based on what is established by Official Mexican How Standards and other applicable provisions."

The exercise of health control shall be applicable to:

(...)

III. Process, use, maintenance, import, export, and final disposal of medical equipment, prostheses, orthoses, functional aids, diagnostic agents, dental supplies, surgical materials, healing and hygienic products, and

(...)

What other provisions apply to the sanitary control of health supplies?

Article 194 of the General Health Law.



Regulatory context in Mexico

What other provisions apply to the health control of medicines and other health supplies?

The Secretariat of Health will issue the Official Mexican Standards to which the process and specifications of the products referred to in this Title must be subject. <u>Medicines and other health supplies shall be</u> <u>regulated by the Pharmacopoeia of the</u> <u>United Mexican States.</u>

> Article 195 of the General Health Law. TITLE TWELFTH Sanitary Control of Products and Services of their Import and Export



Definition

The Pharmacopoeia of the United Mexican


States is the regulatory document of health supplies established in the General Health Law and issued by the Secretariat of Health, which helps to guarantee public health through the consignment of:

- Methods of analysis and reference substances
- Requirements on the specifications of identity, purity and quality of health supplies and their raw materials.





National pharmacopoeias over time





(2)

The Mexican Pharmacopoeia through time





FEUM MEDICAL DEVICE SUPPLEMENT





The Supplement for Medical Devices:

- It has the same level as a NOM.
- It is a document that is constantly updating its contents.
- It is the Secretariat of Health that monitors its compliance.
- May set monographs by product family.
- Establishes General Methods of Analysis, when these apply to more than two monographs, otherwise the specific method is included within the monograph of the device.



SUPPLEMENT FOR MEDICAL DEVICES, 4th EDITION

CONTENT

Chapter of Generalities

Chapter of (333) Solutions and Reagents

- 65 General Methods of Analysis
- 224 Product monographs

53 monographs of Radiopharmaceuticals

10 Appendices:

- Health regulation applicable to DM
- Criteria for MD classification
- Guidelines for obtaining sanitary registration
- MD grouping criteria for health registration purposes
- Application of MD Risk Management
- Preservation and management of reference microbial cultures
- Microbiological analysis of non-sterile products
- Glossary
- Technovigilance activities.
- Biocompatibility. A table for test selection harmonized with ISO 10993 is included.



SALUD

Cuarta edición


<u>MÉXICO</u> 2017





Upgrade process

FEUM update process based on NOM-001-SSA1-2020



C




12:43 p.m.

17/11/2021

10

🦾 20°C \land 🔮 🖫 🕼 📥

.



Cuarto Periodo Inicia el periodo: 01/11/2021 Termina el periodo: 31/12/2021

•

w

P

~

٤

Т

(2)

e

Capacitación

Consultas

Consultas a usuarios

Comentano a publicaciones

Ventas

https://farmacopea.org.mx/consultas.php?m=6&sb=8&f=0

\rightarrow C \triangleq farmace	opea.org.mx/consultas_detalle.php?m=6&pid=23#accordiontab-notifications-34		Q	. ☆	-	:
	Sistemas críticos	+				
	Buenas prácticas de laboratorio	+				
	Dispositivos médicos	—				
	MGA-DM 1712. Resistencia a la corrosión					
	Agujas para toma y recolección de sangre, sencilla y/o múltiple, estériles, desechables					
	Catéter para cateterismo venoso central con equipo de inserción por técnica Seldinger, adulto					
	Catéter pediátrico para cateterismo venoso central con equipo de inserción por técnica Seldinger					
	Concentrador de oxígeno					
	Equipo para drenaje por aspiración para uso postquirúrgico					
	Jeringas de vidrio					
	MGA-DM 0352. Dureza para aceros inoxidables					
	MGA-DM 10993-3 Pruebas de biocompatibilidad. Pruebas para genotoxicidad, carcinogenicidad y toxicidad reproductiva (Informativo)					
	MGA-DM 10993-7 Pruebas de biocompatibilidad. Residuos de esterilización por óxido de etileno (Informativo)					
	Termómetro clínico					
	Envases primarios	+				
	Estadística para ensayos biológicos	+				
s://farmacopea.org.mx/Reposit						





"2021, Año de la Independencia"

COMENTARIOS

Con fundamento en el numeral 6.3.3.1 de la Norma Oficial Mexicana NOM-001-SSA1-2020, se publica el presente proyecto a efecto de que los interesados, a partir del 1º de noviembre y hasta el 31 de diciembre de 2021, lo analicen, evalúen y envien sus observaciones o comentarios en idioma español y con el sustento técnico suficiente ante la CPFEUM, sito en Río Rhin número 57, colonia Cuauhtémoc, código postal 06500, Ciudad de México. Correo electrónico: <u>consultas@farmacopea.org.mx</u>.

DATOS DEL PROMOVENTE

Nombre:	Cargo:	
Institución o empresa:	Dirección:	
Teléfono:	Correo	So
	electrónico:	

Dice	Debe decir	Justificación*
MGA-DM 10993-7 PRUEBAS DE		S Sector Constant Constant
BIOCOMPATIBILIDAD. Residuos de esterilización		
por óxido de etileno (Informativo)		
INTRODUCCION		
Como se indica en la introducción de la norma ISO 11135-1, al determinar la idoneidad del óxido de etileno (OE) para la esterilización de dispositivos médicos, es importante asegurarse de que los niveles de OE residual, etilenclorhidrina (ECH) y Etilenglicol (EG) suponen un riesgo mínimo para el paciente con el uso normal del producto. Por lo tanto, es importante que se considere el uso de materiales alternativos y procesos de esterilización durante el diseño y desarrollo del producto. Se sabe que el OE exhibe una serie de efectos biológicos. En el desarrollo de esta parte de la Norma ISO 10993, se consideraron estos efectos, que incluyen irritación, daño orgánico, mutagenicidad y carcinogenicidad en		

CONSULTA A USUARIOS DE LA FEUM 2021-4


Página 1 de 197

DISPOSITIVOS MÉDICOS

14




Principles at CPFEUM





In the Context of BPR Components of the regulatory framework

Figure 1 Structure of a regulatory framework Jordan in initial init Less detailed Less flexible More prescriptive More complicated to change Laws Standards More detailed More flexible Less perceptive Less complicated to Guidelines change



Kelsen Pyramid



FEUM Process in the Context of GRP

GRP

Principles:

Legality Coherence Independence Impartiality Proportionality Flexibility Clarity Efficiency Transparency

NOM-001-SSA1-2020

Principles:

Representativity Consensus Public consultation Permanent review Openess Harmonization Ethics Social responsibility



The structure of CPFEUM in the context of RPG facilitators

- Political and government-wide support
- Effective organization and good governance supported by leadership
- Inter- and intra-organizational communication, collaboration and coordination
- A robust and well-functioning quality management system
- Sufficient and sustainable financial resources
- Competent human resources
- Ethics and organizational values
- Decision-making process based on data and science

- Excellent linkage and cooperation with NRA
- The structure of the CPFEUM has allowed consistency over 37 years
- There is collaboration with about 50 local institutions and organizations and with the Pharmacopoeias of the world
- There is a QMS
- It is a self-sustaining project, based on the sale of the SRef and publications and trainings.
- There is a young but mature team
- There is a living Code of Ethics
- Agreements by consensus, with objectivity and impartiallity based on science and taking up international standards



Cooperation and Convergence between Pharmacopoeias



USP Convention The Executive Director is a voting delegate

Memorandum of Understanding 1999, 2009, 2018

FEUM-USP Scientific Meeting, every 2 years in CDMX Exchange of publications, work plans and technical consultations Mutual invitations to symposia or activities. Stays for training or understanding of our processes.

Observer member, 2020

Participation in a working group with access and influence in the drafts of new pharmacopeial contents

Collaboration at IMWP

Participation in the 12 International Meetings of the World Pharmacopoeias led by WHO since 2012. The 2022 meeting will be hosted by the CDMX. Participation in monographic drafts of inputs for COVID-19 Participation in 55 Meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations

Pacific Alliance

Recognition of the FEUM as a regional Pharmacopoeia

Farmacop ea Europea



Organización Mundial de la Salud



THANK YOU

QFB Rafael Hernández Medina Deputy Director of Publishing and Publications, Pharmacopoeia of the United States of Mexico rhernandez@farmacopea.org.mx





